

Atty Docket No. 13 CIP CON

Examiner: P. Gambel

Group Art Unit: 1644

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Mark J. EVANS et, al

Serial No. 08/487,283 (Now U.S. Patent 6,355,245)

Filed: June 7, 1995

0483.

For: C-5-SPECIFIC ANTIBODIES FOR

THE TREATMENT OF

INFLAMMATORY DISEASES

(AS AMENDED)

The payment of the small entity fee was inadvertent. It is requested that \$620.00, the difference between the payment of the issue fee as a small entity issue fee and the large entity fee which should have been paid, be charged to Deposit Account No. 01-

This communication and payment of fees additionally serve as notification, in accordance with 37 C.F.R. 1.28(d), of a loss of entitlement to small status as required by 37 C.F.R. 1.27(g)(2).

Respectfully submitted,

Mark Farber

Registration No. 34,159 Attorney for Applicants Alexion Pharmaceuticals, Inc.

352 Knotter Drive Cheshire, CT 06410

(203) 271-8289

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: P. Gambel

In re Application of

Mark J. EVANS et al.

Serial No. 08/487,283

(Now U.S. Patent 6,355,245)

Filed: 7 June 1995 Group Art Unit: 1644

For: C5-SPECIFIC ANTIBODIES FOR

THE TREATMENT OF

INFLAMMATORY DISEASES

(AS AMENDED)

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. § 1.322

The above patent issued on March 12, 2002. In reviewing the published application, Applicants have noted the following errors. It is requested that a Certificate of Correction be published to correct the errors listed below. Immediately following is an explanation of each error. A Certificate of Correction (form PTO/SR/44) is filed concurrently with this Request.

- 1. The issue fee for the instant application was paid on 31 October 2001. Concurrent with the mailing of the issue fee, Applicants mailed an Amendment Under Rule 312 requesting that the specification be amended to include a statement that priority was being claimed to U.S. Application Serial No. 08/311,489 filed on September 23, 1994. This additional claim of priority does not appear in the patent as published. It is requested that this be corrected.
- 2. The application was filed claiming priority to PCT/US95/05688 as a continuation-in-part. This was stated in the Preliminary Amendment filed June 7, 1995 and again in the Amendment filed May 11, 2001 which amended the continuing data. The published patent states that the application was filed as a "continuation", not as a "continuation-in-part", of the PCT application. It is requested that this error be corrected.
- 3. An Amendment filed 11 May 2001 changed the title of the application to "ANTIBODIES TO HUMAN COMPLEMENT COMPONENT C5". This title as amended was correctly shown on the Notice of Allowance and Issue Fee Due. The title on the published application is neither the title as amended nor the title as originally filed. It is requested that the title as amended be printed.
- 4. An Examiner's Amendment was made which was mailed 31 July 2001 with the Notice of Allowance and Issue Fee Due. One of the specific amendments was to amend page 33, line 35, by inserting after "KSSKC epitope" the phrase --(SEQ ID NO:1)--. The amendment was correctly stated by the Examiner but was not correctly printed in the published patent. It is

requested that the patent be corrected to conform to the amendment stated in the Examiner's Amendment.

5. The Sequence Listing as published in the printed patent has numerous errors in the numbering of the amino acid residues. This appears to be due to a problem of improper line wrapping. The numbering shown is different from that as shown in the Sequence Listing submitted for the application. This is an important point because the patent often refers to portions of the sequences by amino acid number. Additionally, the claims refer to specific portions of sequences; e.g., claim 19 refers to specific fragments of SEQ ID NO:8 based on amino acid position number. The numbering of amino acid residues in SEQ ID NO:8 is incorrect as published except for the first line of the sequence. The patent as published therefore is misleading and could cause one to misinterpret the claims. Additionally, certain sequences such as SEQ ID NO:2 begin with "pro" regions that are negatively numbered. The numbers are incorrect as published and it is impossible for someone who merely looks at that sequence to know where the proper numbering should be. Because of these problems, it is requested that the Sequence Listing be corrected as shown on the attached forms PTO/SB/44.

It is urged that each of the above cited errors is clearly disclosed in the prosecution of the patent application and that the errors are the fault of the U.S. Patent and Trademark Office. It is, therefore, urged that no fee is required.

Respectfully submitted,

Stephen A. Saxe

Registration No. 38,609

Alexion Pharmaceuticals, Inc.

352 Knotter Drive

Cheshire, CT 06410

Tel. 203-271-8289

Docket No. 13 CIP CON

113

Page 1 of 61

PATENT NO

: 6,355,245 B1

DATED

: Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On page 🕏 delete the title "C5-SPECIFIC ANTIBODIES FOR THE TREATMENT OF INFLAMMATORY DISEASES" and insert therefor -- ANTIBODIES TO HUMAN COMPLEMENT COMPONENT C5--.

In column 1, lines 1-3, delete the title "C5-SPECIFIC ANTIBODIES FOR THE TREATMENT OF INFLAMMATORY DISEASES" and insert therefor --ANTIBODIES TO **HUMAN COMPLEMENT COMPONENT C5--.**

On page 1, delete the paragraph under Related U.S. Application Data and insert therefor -- Continuation-in-part of application No. PCT/US95/05688, filed on May 1, 1995, which is a continuation-in-part of application No. 08/236,208, filed on May 2, 1994, now Pat. No. 6,074,642, and this patent is also a continuation-in-part of application No. 08/311,489, filed on September 23, 1994, now abandoned.

In column 19, line 54, delete "(SEQ ID NO:1)".

In column 19, line 55, following "KSSKC peptide", insert --(SEQ ID NO:1)--.

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410

PATENT NO. 6,355,245

No. of additional copies

Burden Hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comment on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. (Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO · : 6,355,245 B1

DATED

: Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 55, lines 50-53, and insert therefor:

Val Ile Asp His Gln Gly Thr Lys Ser Ser

Lys Cys Val Arg Gln Lys Val Glu Gly Ser Ser 15

Please delete column 57, lines 22-37, and insert therefor:

Met Gly Leu Leu Gly Ile Leu Cys Phe Leu

Ile Phe Leu Gly Lys Thr Trp Gly Gln Glu Gln Thr Tyr Val

Ile Ser Ala Pro Lys Ile Phe Arg Val Gly Ala Ser Glu Asn

Ile Val Ile Gln Val Tyr Gly Tyr Thr Glu Ala Phe Asp Ala

Thr Ile Ser Ile Lys Ser Tyr Pro Asp Lys Lys Phe Ser Tyr

Ser Ser Gly His Val His Leu Ser Ser Glu Asn Lys Phe Gln

Asn Ser Ala Ile Leu Thr Ile Gln Pro Lys Gln Leu Pro Gly

Gly Gln Asn Pro Val Ser Tyr Val Tyr Leu Glu Val Val Ser

PATENT NO. 6,355,245

MAILING ADDRESS OF SENDER: Stephen A. Saxe Alexion Pharmaceuticals, Inc.

352 Knotter Drive Cheshire, CT 06410



PATENT NO : 6,355,245 B1

DATED : Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 57, lines 38-55, and insert therefor:

Lys His Phe Ser Lys Ser Lys Arg Met Pro Ile Thr Tyr Asp

Asn Gly Phe Leu Phe Ile His Thr Asp Lys Pro Val Tyr Thr 105 110 115

Pro Asp Gln Ser Val Lys Val Arg Val Tyr Ser Leu Asn Asp

Asp Leu Lys Pro Ala Lys Arg Glu Thr Val Leu Thr Phe Ile

Asp Pro Glu Gly Ser Glu Val Asp Met Val Glu Glu Ile Asp

His Ile Gly Ile Ile Ser Phe Pro Asp Phe Lys Ile Pro Ser 165 170

Asn Pro Arg Tyr Gly Met Trp Thr Ile Lys Ala Lys Tyr Lys 175 180 185

Glu Asp Phe Ser Thr Thr Gly Thr Ala Tyr Phe Glu Val Lys 190 195 200

Glu Tyr Val Leu Pro His Phe Ser Val Ser Ile Glu Pro Glu 205 210 215

Please delete column 59, lines 1-4, and insert therefor:

Tyr Asn Phe Ile Gly Tyr Lys Asn Phe Lys Asn Phe Glu Ile 220 225 230

Thr Ile Lys Ala Arg Tyr Phe Tyr Asn Lys Val Val Thr Glu \$235\$

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410 PATENT NO. 6,355,245



PATENT NO : 6,355,245 B1

DATED : Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 59, lines 5-28, and insert therefor:

Ala 245	Asp	Val	Tyr	Ile	Thr 250	Phe	Gly	Ile	Arg	Glu 255	Asp	Leu	Lys	
Asp	Asp 260	Gln	Lys	Glu	Met	Met 265	Gln	Thr	Ala	Met	Gln 270	Asn	Thr	
Met	Leu	Ile 275	Asn	Gly	Ile	Ala	Gln 280	Val	Thr	Phe	Asp	Ser 285	Glu	
Thr	Ala	Val	Lys 290	Glu	Leu	Ser	Tyr	Tyr 295	Ser	Leu	Glu	Asp	Leu 300	
Asn	Asn	Lys	Tyr	Leu 305	Tyr	Ile	Ala	Val	Thr 310	Val	Ile	Glu	Ser	
Thr 315	Gly	Gly	Phe	Ser	Glu 320	Glu	Ala	Glu	Ile	Pro 325	Gly	Ile	Lys	
Tyr	Val 330	Leu	Ser	Pro	Tyr	Lys 335		Asn	Leu	Val	Ala 340	Thr	Pro	
Leu	Phe	Leu 345	Lys	Pro	Gly	Ile	Pro 350	Tyr	Pro	Ile	Lys	Val 355	Gln	
Val	Lys	Asp	Ser 360	Leu	Asp	Gln	Leu	Val 365	Gly	Gly	Val	Pro	Val 370	
Ile	Leu	Asn	Ala	Gln 375		Ile	Asp	Val	Asn 380	Gln	Glu	Thr	Ser	
Asp 385		Asp	Pro	Ser	Lys 390		Val	Thr	Arg	Val 395	Asp	Asp	Gly	
Val	Ala 400		Phe	Val	Leu	Asn 405		Pro	Ser	Gly	Val 410	Thr	Val	

PATENT NO. 6,355,245

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410



PATENT NO : 6,355,245 B1

DATED : Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 59, lines 29-52; and insert therefor:

PATENT NO. 6,355,245

No. of additional copies

 \Rightarrow °

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410

PATENT NO : 6,355,245 B1

DATED : Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 61, lines 1-26, and insert therefor:

Trp Val Ala Leu Ala Ala Val Asp Ser Ala Val Tyr Gly Val

Gln Arg Gly Ala Lys Lys Pro Leu Glu Arg Val Phe Gln Phe

Leu Glu Lys Ser Asp Leu Gly Cys Gly Ala Gly Gly Leu 615

Asn Asn Ala Asn Val Phe His Leu Ala Gly Leu Thr Phe Leu 630

Thr Asn Ala Asn Ala Asp Asp Ser Gln Glu Asn Asp Glu Pro

Cys Lys Glu Ile Leu Arg Pro Arg Arg Thr Leu Gln Lys Lys 655

Ile Glu Glu Ile Ala Ala Lys Tyr Lys His Ser Val Val Lys 670

Lys Cys Cys Tyr Asp Gly Ala Cys Val Asn Asn Asp Glu Thr

Cys Glu Gln Arg Ala Ala Arg Ile Ser Leu Gly Pro Arg Cys

Ile Lys Ala Phe Thr Glu Cys Cys Val Val Ala Ser Gln Leu

Arg Ala Asn Ile Ser His Lys Asp Met Gln Leu Gly Arg Leu

His Met Lys Thr Leu Leu Pro Val Ser Lys Pro Glu Ile Arg

Ser Tyr Phe Pro Glu Ser Trp Leu Trp Glu Val His Leu Val

PATENT NO. 6,355,245

No. of additional copies

MAILING ADDRESS OF SENDER: Stephen A. Saxe Alexion Pharmaceuticals, Inc.

352 Knotter Drive Cheshire, CT 06410

PATENT NO

: 6,355,245 B1

DATED

: Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 61, lines 27-52, and insert therefor:

Pro Arg Arg Lys Gln Leu Gln Phe Ala Leu Pro Asp Ser Leu Thr Thr Trp Glu Ile Gln Gly Ile Gly Ile Ser Asn Thr Gly Ile Cys Val Ala Asp Thr Val Lys Ala Lys Val Phe Lys Asp Val Phe Leu Glu Met Asn Ile Pro Tyr Ser Val Val Arg Gly Glu Gln Ile Gln Leu Lys Gly Thr Val Tyr Asn Tyr Arg Thr Ser Gly Met Gln Phe Cys Val Lys Met Ser Ala Val Glu Gly Ile Cys Thr Ser Glu Ser Pro Val Ile Asp His Gln Gly Thr Lys Ser Ser Lys Cys Val Arg Gln Lys Val Glu Gly Ser Ser Ser His Leu Val Thr Phe Thr Val Leu Pro Leu Glu Ile Gly 880 Leu His Asn Ile Asn Phe Ser Leu Glu Thr Trp Phe Gly Lys 895 Glu Ile Leu Val Lys Thr Leu Arg Val Val Pro Glu Gly Val Lys Arg Glu Ser Tyr Ser Gly Val Thr Leu Asp Pro Arg Gly Ile Tyr Gly Thr Ile Ser Arg Arg Lys Glu Phe Pro Tyr Arg

PATENT NO. 6,355,245

No. of additional copies

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410

PATENT NO : 6,355,245 B1

DATED : Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 63, lines 1-26, and insert therefor:

Ile Pro Leu Asp Leu Val Pro Lys Thr Glu Ile Lys Arg Ile

Leu Ser Val Lys Gly Leu Leu Val Gly Glu Ile Leu Ser Ala 960 965 970

Val Leu Ser Gln Glu Gly Ile Asn Ile Leu Thr His Leu Pro 975 980 985

Lys Gly Ser Ala Glu Ala Glu Leu Met Ser Val Val Pro Val 990 995 1000

Phe Tyr Val Phe His Tyr Leu Glu Thr Gly Asn His Trp Asn $1005 \hspace{1.5cm} 1010$

Ile Phe His Ser Asp Pro Leu Ile Glu Lys Gln Lys Leu Lys 1015 \$1020\$ 1025

Lys Lys Leu Lys Glu Gly Met Leu Ser Ile Met Ser Tyr Arg 1030 1035 1040

Asn Ala Asp Tyr Ser Tyr Ser Val Trp Lys Gly Gly Ser Ala 1045 1050 1055

Ser Thr Trp Leu Thr Ala Phe Ala Leu Arg Val Leu Gly Gln

Val Asn Lys Tyr Val Glu Gln Asn Gln Asn Ser Ile Cys Asn 1075 1080

Ser Leu Leu Trp Leu Val Glu Asn Tyr Gln Leu Asp Asn Gly

Ser Phe Lys Glu Asn Ser Gln Tyr Gln Pro Ile Lys Leu Gln 1100 1105 1110

Gly Thr Leu Pro Val Glu Ala Arg Glu Asn Ser Leu Tyr Leu

PATENT NO. 6,355,245

MAILING ADDRESS OF SENDER: Stephen A. Saxe

Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410



PATENT NO : 6,355,245 B1

DATED : Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 63, lines 27-52, and insert therefor:

Thr Ala Phe Thr Val Ile Gly Ile Arg Lys Ala Phe Asp Ile

Cys Pro Leu Val Lys Ile Asp Thr Ala Leu Ile Lys Ala Asp 1145 1150

Asn Phe Leu Leu Glu Asn Thr Leu Pro Ala Gln Ser Thr Phe 1155 1160 1165

Thr Leu Ala Ile Ser Ala Tyr Ala Leu Ser Leu Gly Asp Lys

Thr His Pro Gln Phe Arg Ser Ile Val Ser Ala Leu Lys Arg

Glu Ala Leu Val Lys Gly Asn Pro Pro Ile Tyr Arg Phe Trp 1200 1205 1210

Lys Asp Asn Leu Gln His Lys Asp Ser Ser Val Pro Asn Thr 1215 1220

Gly Thr Ala Arg Met Val Glu Thr Thr Ala Tyr Ala Leu Leu 1225 1230 1235

Thr Ser Leu Asn Leu Lys Asp Ile Asn Tyr Val Asn Pro Val 1240 1245 1250

Ile Lys Trp Leu Ser Glu Glu Gln Arg Tyr Gly Gly Gly Phe

Tyr Ser Thr Gln Asp Thr Ile Asn Ala Ile Glu Gly Leu Thr 1270 1275 1280

Glu Tyr Ser Leu Leu Val Lys Gln Leu Arg Leu Ser Met Asp 1285 1290

Ile Asp Val Ser Tyr Lys His Lys Gly Ala Leu His Asn Tyr 1295 1300 1305

PATENT NO. <u>6,355,245</u>

No. of additional copies

⇒ ∘

MAILING ADDRESS OF SENDER:
Stephen A. Saxe
Alexion Pharmaceuticals, Inc.
352 Knotter Drive
Cheshire, CT 06410

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. (Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO : 6,355,245 B1

DATED

: Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 65, lines 1-26, and insert therefor:

Lys Met Thr Asp Lys Asn Phe Leu Gly Arg Pro Val Glu Val 1315

Leu Leu Asn Asp Asp Leu Ile Val Ser Thr Gly Phe Gly Ser 1330

Gly Leu Ala Thr Val His Val Thr Thr Val Val His Lys Thr 1345

Ser Thr Ser Glu Glu Val Cys Ser Phe Tyr Leu Lys Ile Asp 1360 1355

Thr Gln Asp Ile Glu Ala Ser His Tyr Arg Gly Tyr Gly Asn 1370 1365

Ser Asp Tyr Lys Arg Ile Val Ala Cys Ala Ser Tyr Lys Pro

Ser Arg Glu Glu Ser Ser Ser Gly Ser Ser His Ala Val Met 1395

Asp Ile Ser Leu Pro Thr Gly Ile Ser Ala Asn Glu Glu Asp 1410

Leu Lys Ala Leu Val Glu Gly Val Asp Gln Leu Phe Thr Asp 1425

Tyr Gln Ile Lys Asp Gly His Val Ile Leu Gln Leu Asn Ser 1440

Ile Pro Ser Ser Asp Phe Leu Cys Val Arg Phe Arg Ile Phe 1455 1450

Glu Leu Phe Glu Val Gly Phe Leu Ser Pro Ala Thr Phe Thr 1470

Val Tyr Glu Tyr His Arg Pro Asp Lys Gln Cys Thr Met Phe 1485

PATENT NO. 6,355,245

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410



Approved for use through 01/31/2004. OMB 0651-0033 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Susan M Petrosemolo

petrosemolos@alxn.com

Clinical Accounts Associate

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO

: 6,355,245 B1

DATED

: Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 65, lines 27-50, and insert therefor:

Tyr Ser Thr Ser Asn Ile Lys Ile Gln Lys Val Cys Glu Gly 1495

Ala Ala Cys Lys Cys Val Glu Ala Asp Cys Gly Gln Met Gln 1510 1505

Glu Glu Leu Asp Leu Thr Ile Ser Ala Glu Thr Arg Lys Gln 1525

Thr Ala Cys Lys Pro Glu Ile Ala Tyr Ala Tyr Lys Val Ser 1535 1540

Ile Thr Ser Ile Thr Val Glu Asn Val Phe Val Lys Tyr Lys 1550 1555

Ala Thr Leu Leu Asp Ile Tyr Lys Thr Gly Glu Ala Val Ala 1565 1570

Glu Lys Asp Ser Glu Ile Thr Phe Ile Lys Lys Val Thr Cys 1580

Thr Asn Ala Glu Leu Val Lys Gly Arg Gln Tyr Leu Ile Met

Gly Lys Glu Ala Leu Gln Ile Lys Tyr Asn Phe Ser Phe Arg 1610

Tyr Ile Tyr Pro Leu Asp Ser Leu Thr Trp Ile Glu Tyr Trp 1620

Pro Arg Asp Thr Thr Cys Ser Ser Cys Gln Ala Phe Leu Ala 1635

Asn Leu Asp Glu Phe Ala Glu Asp Ile Phe Leu Asn Gly Cys 1650 1645

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410

PATENT NO. 6,355,245



PATENT NO : 6,355,245 B1

: Mar. 12, 2002 DATED

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 81, lines 18-47, and insert therefor:

	GAC Asp					30
	CTG Leu					60
	ATC Ile					90
	GGT Gly					120
	GGA Gly					150
	GCA Ala					180
	AGG Arg					210
-	TAT Tyr					240
	 GAC Asp	-				270
	GTG Val					300

PATENT NO. 6,355,245

No. of additional copies

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410

PATENT NO : 6,355,245 B1

DATED : Mar. 12, 2002

INVENTOR(S) : Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 81, line 48, through column 83, line 21, and insert therefor:

		AAG Lys 105				330
		GGG Gly 115				360
		GGG Gly 125			,	390
		GCC Ala 135				420
		AAG Lys 145				450
		TTC Phe 155				480
		CAG Gln 165				510
		GGT Gly 175				540
	 	 GAG Glu 185	 	 		570
		GCA Ala 195				600

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410 PATENT NO. <u>6,355,245</u>

No. of additional copies



Burden Hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comment on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PATENT NO : 6,355,245 B1

DATED

: Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 83, lines 22-36, and insert therefor:

			GCC Ala 205				630
			GAG Glu 215				660
			TAT Tyr 225				690
			TTC Phe 235			GCA Ala 240	720
	 	-	ACC Thr 245		TGA		747

Please delete column 83, lines 46-57, and insert therefor:

30				GAT Asp	
60				CTG Leu	
90				ATC Ile	
120				GGC Gly	

PATENT NO. 6,355,245

No. of additional copies

MAILING ADDRESS OF SENDER: Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive

Cheshire, CT 06410

PATENT NO

: 6,355,245 B1

DATED

: Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 85, lines 1-30, and insert therefor:

AAA CCT GGG AAA Lys Pro Gly Lys		150
TAC GGT GCG ACG Tyr Gly Ala Thr		180
CCT TCT CGC TTC Pro Ser Arg Phe		210
ACG GAT TTC ACT Thr Asp Phe Thr		240
CAG CCT GAA GAC Gln Pro Glu Asp		270
CAG AAC GTT TTA Gln Asn Val Leu		300
GGA CAG GGT ACC Gly Gln Gly Thr		330
ACT GGC GGT GGT Thr Gly Gly Gly		360
TCT GGT GGT GGC Ser Gly Gly Gly		390
GTG CAA TCC GGC Val Gln Ser Gly		420

PATENT NO. 6,355,245

Stephen A. Saxe Alexion Pharmaceuticals, Inc.

352 Knotter Drive

MAILING ADDRESS OF SENDER:

Cheshire, CT 06410



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. (Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO

: 6,355,245 B1

DATED

: Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 85, lines 31-60, and insert therefor:

			GTC Val							450
			ATT Ile							480
CAA Gln	TGG Trp	GTG Val	CGT Arg	CAG Gln 165	GCC Ala	CCC Pro	GGG Gly	CAG Gln	GGC Gly 170	510
			ATG Met							540
			ACC Thr							570
			GTT Val							600
			ACA Thr							630
			TCG Ser		Asp					660
					Phe				AGC Ser 230	690
CCG Pro	AAT	TGG	TAT Tyr	TTT Phe	Asp	GTT Val	TGG	GGT Gly	CAA Gln 240	720

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410

PATENT NO. 6,355,245



PATENT NO : 6,355,245 B1

DATED : Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 87, lines 1-3, and insert therefor:

GGA ACC CTG GTC ACT GTC TCG AGC TGA 747
Gly Thr Leu Val Thr Val Ser Ser
245

Please delete column 87, lines 13-36, and insert therefor:

ATG GGA ATC CAA GGA GGG T Met Gly Ile Gln Gly Gly S -25 -20	 30
GGG CTG CTG CTC GTC CTG GGly Leu Leu Leu Val Leu F-15	60
CAT TCA GGT CAT AGC CTG C His Ser Gly His Ser Leu C -5	90
ATG ACT CAG TCT CCA GCT T Met Thr Gln Ser Pro Ala S 10	 120
TCT GTG GGA GAA ACT GTC A Ser Val Gly Glu Thr Val T 20	 150
GGA GCA AGT GAG AAT ATT 1 Gly Ala Ser Glu Asn Ile 1 30	 180
AAT TGG TAT CAG CGG AAA C Asn Trp Tyr Gln Arg Lys C 40	210
CCT CAG CTC CTG ATC TAT C Pro Gln Leu Leu Ile Tyr C 50	 240

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410 PATENT NO. 6,355,245



PATENT NO

: 6,355,245 B1

DATED

: Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 87, line 37, through column 89, line 9, and insert therefor:

TTG GCA GAT GGC ATG TCA TCG AGG TTC AGT Leu Ala Asp Gly Met Ser Ser Arg Phe Ser 60 65	270
GGC AGT GGA TCT GGT AGA CAG TAT TAT CTC Gly Ser Gly Ser Gly Arg Gln Tyr Tyr Leu 70 75	300
AAG ATC AGT AGC CTG CAT CCT GAC GAT GTT Lys Ile Ser Ser Leu His Pro Asp Asp Val 80 85	330
GCA ACG TAT TAC TGT CAA AAT GTG TTA AAT Ala Thr Tyr Tyr Cys Gln Asn Val Leu Asn 90 95	360
ACT CCT CTC ACG TTC GGT GCT GGG ACC AAG Thr Pro Leu Thr Phe Gly Ala Gly Thr Lys 100 105	390
TTG GAG CTG AAA CGA ACT GTG GCT GCA CCA Leu Glu Leu Lys Arg Thr Val Ala Ala Pro 110 115	420
TCT GTC TTC ATC TTC CCG CCA TCT GAT GAG Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 120 125	450
CAG TTG AAA TCT GGA ACT GCC TCT GTT GTG Gln Leu Lys Ser Gly Thr Ala Ser Val Val 130 135	480
TGC CTG CTG AAT AAC TTC TAT CCC AGA GAG Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu 140 145	510
GCC AAA GTA CAG TGG AAG GTG GAT AAC GCC Ala Lys Val Gln Trp Lys Val Asp Asn Ala 150 155	540

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410

PATENT NO. _6,355,245



PATENT NO : 6,355,245 B1

DATED : Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 89, lines 10-29, and insert therefor:

						•				
CTC	CAA	TCG	GGT	AAC	TCC	CAG	GAG	AGT	GTC	570
			Gly							
пси	· · · ·		01,	160					165	
474	CAG	CAG	GAC	AGC	AAG	GAC	AGC	ACC	TAC	600
			Asp							
1111	014	02		170	-1-				175	
AGC	CTC	AGC	AGC	ACC	CTG	ACG	CTG	AGC	AAA	630
			Ser							•
001				180					185	
GCA	GAC	TAC	GAG	AAA	CAC	AAA	GTC	TAC	GCC	660
			Glu							
7.10	nop.	- 1 -		190		-,-		•	195	
TGC	GAA	GTC	ACC	CAT	CAG	GGC	CTG	AGC	TCG	69
			Thr							
Cys	0.0			200	•				205	
CCC	GTC	ACA	AAG	AGC	TTC	AAC	AGG	GGA	GAG	72
			Lys							
			-,-	210			_	•	215	
TGT	TAG									. 72
Cys										
Cys										

Please delete column 89, lines 39-44, and insert therefor:

		GTT Val			3	30
		GGT Gly			1	60

PATENT NO. 6,355,245

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. (Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE **CERTIFICATE OF CORRECTION**

PATENT NO

: 6,355,245 B1

DATED

: Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 89, line 45, through column 91, line 15, and insert therefor:

	CAG Gln 5					90
	GGG Gly 15					120
	ACT Thr 25					150
	CAG Gln 35					180
	CTT Leu 45					210
	AGT Ser 55					240
	AAG Lys 65					270
	TCC Ser 75					300
 	 AGC Ser 85	Leu				330
	TAC Tyr 95	Сув				360

PATENT NO. 6,355,245

Stephen A. Saxe Alexion Pharmaceuticals, Inc.

352 Knotter Drive Cheshire, CT 06410

MAILING ADDRESS OF SENDER:

PATENT NO : 6,355,245 B1

DATED : Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 91, lines 16-45, and insert therefor:

AGT Ser					390
GGC Gly					420
GCC Ala					450
CTG Leu					480
GGC Gly					510
GAC Asp					540
TGG Trp					570
CAC His					600
GGA Gly					630
GTG Val					660

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410 PATENT NO. 6,355,245



PATENT NO : 6,355,245 B1

DATED : Mar. 12, 2002

INVENTOR(S) : Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 91, lines 46-54, and insert therefor:

TGC AAC GTG AA Cys Asn Val As 205	690
AAG GTG GAC AA Lys Val Asp Ly 215	720
TGT GAC AAA AC Cys Asp Lys Th 225	750

Please delete column 93, lines 4-21, and insert therefor:

ATG Met					30
			GTC Val		60
			GGC Gly		90
			GTC Val		120
			ATT Ile		150
			CGT Arg		180

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410 PATENT NO. 6,355,245



: 6,355,245 B1 PATENT NO

: Mar. 12, 2002 DATED

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 93, lines 22-51, and insert therefor:

		CTG Leu 45				•	210
 		TCT Ser 55					240
		CAG Gln 65					270
		TCG Ser 75			ATG Met		300
		AGC Ser 85					330
		TAT Tyr 95					360
		CCG Pro 105					390
 	-	GGA Gly 115				•	420
 		ACC Thr 125					450
		CCC Pro 135					480

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410

PATENT NO. 6,355,245

PATENT NO

: 6,355,245 B1

DATED

: Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please column 93, line 52, through column 95, line 27, and insert therefor:

		GCC Ala				510
		CCC Pro		 		540
		GGC Gly				570
		 CCG Pro	 	 		600
		TCC Ser				630
		AGC Ser				660
	-	 AAC Asn	 	 		690
		GTG Val				720
		GAC Asp	-	 	TAA	750

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410

PATENT NO. 6,355,245



PATENT NO : 6,355,245 B1

DATED : Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 95, line 31, through column 97, line 3, and insert therefor:

	TGG Trp					30
	GTA Val					60
	CTG Leu					90
	CCA Pro					120
	GCT Ala					150
	ATT Ile					180
	GGC Gly					210
	GGC Gly					240
	TTT Phe			_	 	270
	ACT Thr					300

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410 PATENT NO. 6,355,245

No. of additional copies



Burden Hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comment on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PATENT NO

: 6,355,245 B1

DATED

: Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 97, lines 4-33, and insert therefor:

		AGC Ser 85						330
		TAT Tyr 95						360
		CCG Pro 105						390
		GGA Gly 115						420
		ACC Thr 125						450
		CCC Pro 135						480
		GCG Ala 145						510
		TTC Phe 155						540
		TCA Ser 165	Gly			Gly		570
			Pro			TCC Ser		600

PATENT NO. 6,355,245

No. of additional copies

MAILING ADDRESS OF SENDER: Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. (Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE **CERTIFICATE OF CORRECTION**

PATENT NO

: 6,355,245 B1

DATED

: Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 97, lines 34-48, and insert therefor:

		TCC Ser		 		•	630
		AGC Ser				(660
		AAC Asn				(690
		GTG Val					720
		GAC Asp		 -	TAA		750

Please delete column 99, lines 2-13, and insert therefor:

230

	ATC Ile		 	 	 30	Э
	CTG Leu				 60	Э
	GGT Gly		 	 	 90	3
	CAG Gln				 120)

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410

225

PATENT NO. 6,355,245



PATENT NO

: 6,355,245 B1

DATED

: Mar. 12, 2002

INVENTOR(S) : Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 99, lines 14-43, and insert therefor:

TCT GTG GGC GAT Ser Val Gly Asp		150
GGC GCC AGC GAA Gly Ala Ser Glu		180
AAC TGG TAT CAA Asn Trp Tyr Gln		210
CCG AAG CTT CTG Pro Lys Leu Leu		240
CTG GCA GAT GGA Leu Ala Asp Gly		270
GGA TCC GGC TCC Gly Ser Gly Ser		300
ACC ATC AGC AGT Thr Ile Ser Ser		330
GCT ACG TAT TAC		360
ACT CCG TTG ACT Thr Pro Leu Thr		390
GTG GAA ATA AAA Val Glu Ile Lys		420

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410

PATENT NO. <u>6,355,245</u>

No. of additional copies



Burden Hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comment on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PATENT NO : 6,355,245 B1

DATED : N

: Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 99, line 44, through column 101, line 17, and insert therefor:

TCT Ser	GTC Val	Phe	ATC Ile	TTC Phe 120	CCG Pro	CCA Pro	TCT Ser	GAT Asp	GAG Glu 125	45
CAG Gln	TTG Leu	Lys	TCT Ser	GGA Gly 130	ACT Thr	GCC Ala	TCT Ser	GTT Val	GTG Val 135	48
тgc	CTG Leu	CTG Leu	AAT Asn	AAC Asn 140	TTC Phe	TAT Tyr	CCC Pro	AGA Arg	GAG Glu 145	51
GCC Ala	AAA Lys	GTA Val	CAG Gln	TGG Trp 150	AAG Lys	GTG Val	GAT Asp	AAC Asn	GCC Ala 155	544
CTC Leu	CAA Gln	TCG Ser	GGT Gly	AAC Asn 160	TCC Ser	CAG Gln	GAG Glu	AGT Ser	GTC Val 165	570
ACA Thr	GAG Glu	CAG Gln	GAC Asp	AGC Ser 170	AAG Lys	GAC Asp	AGC Ser	ACC Thr	TAC Tyr 175	600
AGC Ser	CTC Leu	AGC Ser	AGC Ser	ACC Thr 180	CTG Leu	ACG Thr	CTG Leu	AGC Ser	AAA Lys 185	630
GCA Ala	GAC Asp	TAC Tyr	GAG Glu	AAA Lys 190	CAC His	AAA Lys	GTC Val	TAC Tyr	GCC Ala 195	660
TGC Cys	GAA Glu	GTC Val	ACC Thr	CAT His 200	CAG Gln	GGC Gly	CTG Leu	AGC Ser	TCG Ser 205	690
CCC Pro	GTC Val	ACA Thr	AAG Lys	AGC Ser 210	TTC Phe	AAC Asn	AGG Arg	GGA Gly	GAG Glu 215	720
TGT Cys	TAG									726

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410 PATENT NO. 6.355,245



PATENT NO : 6,355,245 B1

DATED : Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 101, lines 28-57, and insert therefor:

	GGA Gly					30
	CTG Leu	 	 			60
	TCA Ser					90
	ACC Thr					120
	GTG Val					150
	GCC Ala					180
	TGG Trp					210
	AAG Lys					240
	GCA Ala	 	 	 	 -	. 270
	TCC Ser					. 300

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410 PATENT NO. <u>6,355,245</u>



PATENT NO : 6,355,245 B1

DATED : Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 103, lines 1-30, and insert therefor:

ACC ATC AGC AG Thr Ile Ser Se		330
GCT ACG TAT TA		360
ACT CCG TTG ACT	 	390
GTG GAA ATA AA Val Glu Ile Ly		420
TCT GTC TTC ATC	 	450
CAG TTG AAA TC Gln Leu Lys Se		480
TGC CTG CTG AA Cys Leu Leu As		510
GCC AAA GTA CA Ala Lys Val Gl		540
CTC CAA TCG GG Leu Gln Ser Gl		570
ACA GAG CAG GA Thr Glu Gln As		600

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410 PATENT NO. 6,355,245

No. of additional copies



Burden Hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comment on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PATENT NO : 6,355,245 B1

DATED : Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 103, lines 31-44, and insert therefor:

				ACC						630
Ser	Leu	Ser	Ser	Thr	Leu	Thr	Leu	Ser	Lys	
				180					185	
GCA	GAC	TAC	GAG	AAA	CAC	AAA	GTC	TAC	GCC	660
Ala	Asp	Tyr	Glu	Lys	His	Lys	Val	Tyr	Ala	
				190		-		_	195	
TGC	GAA	GTC	ACC	CAT	CAG	GGC	CTG	AGC	TCG	690
Cys	Glu	Va1	Thr	His	Gln	Glv	Leu	Ser	Ser	
•				200					205	
ccc	GTC	ACA	AAG	AGC	TTC	AAC	AGG	GGA	GAG	720
				Ser						
		••••	~, 5	210			9	017	215	
									2.1.3	
TGT	тас									726
Cys	ing									120
Cys										

Please delete column 103, line 55, through column 105, line 9, and insert therefor:

				GTC Val					CTG Leu		30
				CTC							60
GIĀ	Leu	Leu	-10	Leu	Trp	Leu	Arg	-5	Ala		
AGA	TGT	GAT	ATC	CAG	ATG	ACC	CAG	TCC	CCG		90
Arg	Cys	Asp 1	Ile	Gln	Met	Thr 5	Gln	Ser	Pro		
				GCC							120
Ser	Ser 10	Leu	Ser	Ala	Ser	Val 15	Gly	Asp	Arg		

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410 PATENT NO. 6,355,245



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. (Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO : 6,355,245 B1

DATED : Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 105, lines 10-39, and insert therefor:

	ACC										150
Val	Thr	Ile	Thr	Cys	Gly		Ser	Glu	Asn		
	20					25					
							m = m	C 3 3	CNC		180
ATC	TAT	GGC	GCG	CTG	AAC	TGG	TAI	CAA	CAG Cln		100
Ile	Tyr	GIŢ	Ala	rea	Asn	35	ıyı	GIII	GIII		
	30					33					
ΔΔΔ	CCC	GGG	AAA	GCT	CCG	AAG	CTT	CTG	ATT		210
	Pro										
,	40	,	-1-			45					
TAC	GGT	GCG	ACG	AAC	CTG	GCA	GAT	GGA	GTC		240
Tyr	Gly	Ala	Thr	Asn	Leu	Ala	Asp	Gly	Val		
	50					55					
				m.c/m	CC.	TCC	ccc	TCC	CCA		270
	TCT Ser										
Pro		Arg	Pne	ser	GIY	65	GIY	Ser	GIY		
	60					0,5					
۸CG	GAT	TTC	ACT	CTG	ACC	ATC	AGC	AGT	CTG		300
Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu		
	70		•			75					
CAG	CCT	GAA	GAC	TTC	GCT	ACG	TAT	TAC	TGT		330
Gln	Pro	Glu	Asp	Phe	Ala			Tyr	Cys		
	80					85					
a		- Cm-	n maria	אאי	አርጥ	CCC	יייי	: אריד	TTC		360
CAG	AAC	Unl	TOU	AAI	Thr	Pro	Len	Thr	Phe		
GII	90		. Leu	ASII		95					
	,,										
GGA	CAG	GGT	ACC	AAG	GTG	GAA	ATA	AAA A	CGA		39
Gly	Gln	Gly	Thr	Lys	Val	Glu	116	Lys	Arg		
	100			_		105					
											42
AC1	GTG	GC1	C GCA	CCA	TCT	GTC	TTC	ATC	TTC		42
Thi			a Ala	Pro	Ser			9 116	Phe		
	110)				115	•				

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410 PATENT NO. 6,355,245



PATENT NO : 6,355,245 B1

DATED : Mar. 12, 2002

INVENTOR(S) : Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 105, line 40, through column 107, line 9, and insert therefor:

		GAG Glu					450
		GTG Val					480
 	 	GAG Glu					510
		GCC Ala					540
 	 	GTC Val					570 ·
		TAC Tyr					600
 	 	AAA Lys					630
		GCC Ala		Val			660
 	 	TCG Ser	 				690
 	 	GAG Glu	TAG				711

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410 PATENT NO. 6,355,245



PATENT NO : 6,355,245 B1

DATED : Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 107, lines 20-49, and insert therefor:

	GTT ATT CTC Val Ile Leu	 . 30
	GGC GTC CAC Gly Val His	60
	TCC GGC GCC Ser Gly Ala	90
	TCA GTC AAA Ser Val Lys	 120
	TAT ATT TTT Tyr Ile Phe	150
	GTG CGT CAG Val Arg Gln	180
	TGG ATG GGT Trp Met Gly	210
	AGC ACC GAA Ser Thr Glu	240
	CGT GTT ACT Arg Val Thr	 270
	AGT ACA GTA Ser Thr Val	300

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410

PATENT NO. _6,355,245_



PATENT NO

: 6,355,245 B1

DATED

: Mar. 12, 2002

INVENTOR(S) : Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 107, line 50, through column 109, line 21, and insert therefor:

GAG Glu	Leu	Ser	Ser 85	Leu	CGA Arg	Ser	GAC Glu	GAC Asp 90	ACG Thr	330
GCC Ala	GTC Val	TAT	TAT Tyr 95	Cys	GCG Ala	CGT Arg	TAT Tyr	TTT Phe 100	TTT Phe	360
GGT Gly	TCT Ser	AGC Ser	CCG Pro 105	AAT Asn	TGG Trp	TAT	TTT Phe	GAT Asp 110	GTT Val	390
TGG Trp	GGT Gly	CAA Gln	GGA Gly 115	ACC Thr	CTG Leu	GTC Val	ACT Thr	GTC Val 120	TCG Ser	420
AGC Ser	GCC Ala	TCC Ser	ACC Thr 125	AAG Lys	GGC Gly	CCA Pro	TCG Ser	GTC Val 130	TTC Phe	450
CCC	CTG Leu	GCG Ala	CCC Pro 135	TCC Ser	TCC Ser	AAG Lys	AGC Ser	ACC Thr 140	TCT Ser	480
GGG Gly	GGC Gly	ACA Thr	GCG Ala 145	GCC Ala	CTG Leu	GGC Gly	TGC Cys	CTG Leu 150	GTC Val	510
AAG Lys	GAC Asp	TAC Tyr	TTC Phe 155	CCC Pro	GAA Glu	CCG Pro	GTG Val	ACG Thr 160	GTG Val	540
TCG Ser	TGG Trp	AAC Asn	TCA Ser 165	GGC Gly	GCC Ala	CTG Leu	ACC Thr	AGC Ser 170	GGC Gly	570
GTG Val	CAC His	ACC Thr	TTC Phe 175	CCG Pro	GCT Ala	GTC Val	CTA Leu	CAG Gln 180	TCC Ser	600

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410

PATENT NO. <u>6,355,245</u>



PATENT NO : 6,355,245 B1

DATED : Mar. 12, 2002

INVENTOR(S) : Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 109, lines 22-36, and insert therefor:

	GGA									•	630
ser	Gly	Leu	19r 185	ser	Leu	ser	ser	190	vai		
ACC	GTG	CCC	TCC	AGC	AGC	TTG	GGC	ACC	CAG	•	660
Thr	Val	Pro	Ser	Ser	Ser	Leu	Gly	Thr	Gln		
			195					200			
	TAC										690
Thr	Tyr	Ile	Cys	Asn	Val	Asn	His	Lys	Pro		
			205					210			
AGC	AAC	ACC	AAG	GTG	GAC	AAG	AAA	GTT	GAG		720
Ser	Asn	Thr	Lys	Val	Asp	Lys	Lys	Val	Glu		
			215		٠	•	•	220			
CCC	AAA	TCT	TGT	GAC	AAA	ACT	CAC	ACA	TAA		750
Pro	Lys	Ser	Cys	Asp	Lys	Thr	His	Thr			
	•		225	-	•			230			

Please delete column 109, lines 47-58, and insert therefor:

_	 	 CAG Gln 5	 	 	 30
		GCC Ala 15		 	 60
		 TGC Cys 25	 	 	 90
		CTG Leu 35			120

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410

PATENT NO. _6,355,245_



PATENT NO

: 6,355,245 B1

DATED

: Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 111, lines 1-30, and insert therefor:

		AAA Lys				15	50
		ACG Thr				18	80
		TTC Phe				2:	10
		ACT Thr				2-	40
		GAC Asp				2	70
		TTA Leu				3	00
		ACC Thr				3	30
		GGT Gly				3	60
		GGC Gly				3	90
					CCA Pro 140	4	20

PATENT NO. 6,355,245

MAILING ADDRESS OF SENDER: Stephen A. Saxe

Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410



PATENT NO

: 6,355,245 B1

DATED

: Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 111, lines 31-60, and insert therefor:

	TCA Ser						450
	TAT Tyr		-				480
	GTG Val						510
	TGG Trp						540
	AGC Ser						570
	CGT Arg						600
	AGT Ser	-	_	–	 		630
	CGA Arg						660
	GCG Ala				 		690
	TGG Trp						720

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410

PATENT NO. 6,355,245



PATENT NO : 6,355,245 B1

DATED : Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 113, lines 1-3 and insert therefor:

GGA ACC CTG GTC ACT GTC TCG AGC TGA 747
Gly Thr Leu Val Thr Val Ser Ser

Please delete column 119, lines 2-25, and insert therefor:

GCC Ala					30
TCT Ser	 	 _	-	 	 60
ACC Thr					90
GAT Asp					120
 TAC Tyr	 	 		 	 150
CTC Leu	 			 _	180
TCT Ser					210
GGG Gly					240

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410 PATENT NO. 6,355,245



PATENT NO

: 6,355,245 B1

DATED

: Mar. 12, 2002

INVENTOR(S) : Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 119, lines 26-55, and insert therefor:

ATT Ile	GAT Asp	CCT Pro	GTG Val	GAG Glu 85	GCT Ala	GAT Asp	GAT Asp	GCT Ala	GCA Ala 90		270
				CAG Gln 95							300
				GGA Gly 105							330
GAA Glu	ATA Ile	AAA Lys	CGG Arg	ACC Thr 115	GGA Gly	GGT Gly	GGC Gly	GGG Gly	TCG Ser 120		360
GGT Gly	GGC Gly	GGG Gly	GGA Gly	TCG Ser 125	GGT Gly	GGC Gly	GGA Gly	GGG Gly	TCG Ser 130	. :	390
GAC Asp	GTC Val	AAG Lys	CTC Leu	GTG Val 135	GAG Glu	TCT Ser	GGG Gly	GGA Gly	GAC Asp 140		420
TTA Leu	GTG Val	AAG Lys	CTT Leu	GGA Gly 145	GGG Gly	TCC Ser	CTG Leu	AAA Lys	CTC Leu 150	•	450
TCC Ser	TGT Cys	GCA Ala	GCC Ala	TCT Ser 155	GGA Gly	TTC Phe	ACC Thr	TTC Phe	AGT Ser 160	4	480
				TCT Ser 165						Ę	510
				CTG Leu 175						5	540

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410

PATENT NO. 6,355,245



Approved for use through 01/31/2004. OMB 0651-0033

Approved for use through 01/31/2004. OMB 0651-0033

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(Also Form PTO-1050) (Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO

: 6,355,245 B1

DATED

: Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 119, line 56, through column 121, line 22, and insert therefor:

ATT	AAT	AGT	AAT	GGT	GAT	AGC	ACC	TAC	TAT		
Ile	Asn	Ser	Asn	Gly	Asp	Ser	Thr	Tyr	Tyr		
				185	-				190		
CCA	GAC	ACT	GTG	AAG	GGC	CGA	TTC	ACC	ATC		
Pro	Asp	Thr	Val	Lys	Gly	Arg	Phe	Thr	Ile		
				195					200		
					***	100	200	CTC	CAT		
TCC	AGA	GAC	AAT	33.	AAG	AGC	ACC	TAN	Acn		
Ser	Arg	Asp	Asn		гуѕ	Ser	Thr	пец	210		
				205					210		
CTG	CAA	ATG	AGC	AGT	CTG	AAG	TCT	GAG	GAC		
Len	Gln	Met	Ser	Ser	Leu	Lys	Ser	Glu	Asp		
Deu	· · · ·			215		•			220		
ACA	GCC	TTG	TAT	TTC	TGT	GTA	AGA	GAG	ACT		
Thr	Ala	Leu	Tyr	Phe	Cys	Val	Arg	Glu	Thr		
				225					230		
							. amà	mmc	CAT		
TAT	TAC	TAC	GGG	ATI	AGT	CCC	77-1	Dhe	GAT		
Туз	Tyr	Tyr	GIA			PIC) vai	PHE	240		
				235					240		
cme	TCC	. ccc	י ארי	. ccc	: ACC	· ACC	GTC	ACC	GTC		
Val	Trr	GIV	Thi	. Glv	Thr	Thi	. Val	Thi	Val		
va.		, 01]		245					250		
TC	TCA	A CTO	GAG	CAC	CAC	CAC	CAC	CAC	CAC		
Se	c Sei	Lei	ı Glı	ı His	His	Hi:	s His	His	His		
				255					260		
TG.	A										

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410

PATENT NO. 6,355,245



PATENT NO

: 6,355,245 B1

DATED

: Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 121, line 32, through column 123, line 3, and insert therefor: ATG GCC GAT ATC CAG ATG ACC CAG TCC CCG

Met 1	Ala	a Asp	ıl.	e Glr	n Met	Th	r Glr	i Se	r Pro		30
TCC	Ser	C CTC	TC0	C GCC Ala	Ser	Val	GGC Gly	GAT Asp	AGG Arg 20		60
GTC Val	ACC	Ile	ACC Thi	C TGC Cys 25	Gly	GCC Ala	AGC Ser	GAA Glu	AAC Asn 30		90
ATC Ile	TAT	GGC	GCG Ala	CTG Leu 35	Asn	TGG	TAT Tyr	CAA Gln	CAG Gln 40		120
AAA Lys	CCC	GGG Gly	AAA Lys	GCT Ala 45	CCG Pro	AAG Lys	CTT Leu	CTG Leu	ATT Ile 50		150
TAC Tyr	GGT Gly	GCG Ala	ACG Thr	AAC Asn 55	CTG Leu	GCA Ala	GAT Asp	GGA Gly	GTC Val 60		180
CCT Pro	TCT Ser	CGC Arg	TTC Phe	TCT Ser 65	GGA Gly	TCC Ser	GGC Gly	TCC Ser	GGA Gly 70	,	210
ACG Thr	GAT Asp	TTC Phe	ACT Thr	CTG Leu 75	ACC Thr	ATC Ile	AGC Ser	AGT Ser	CTG Leu 80		240
CAG Gln	CCT Pro	GAA Glu	GAC Asp	TTC Phe 85	GCT Ala	ACG Thr	TAT Tyr	TAC Tyr	TGT Cys 90		270
CAG Gln	AAC Asn	GTT Val	TTA Leu	AAT Asn 95	ACT Thr	CCG Pro	TTG Leu	ACT Thr	TTC Phe 100		300

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410

PATENT NO. 6,355,245



PATENT NO : 6,355,245 B1

DATED : Mar. 12, 2002

INVENTOR(S) : Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 123, lines 4-33, and insert therefor:

		ACC Thr				330
		GGT Gly				360
		GGC Gly				390
		GGC Gly				420
		GTC Val				450
		ATT Ile				480
		CGT Arg				510
	-	ATG Met				540
		ACC Thr				570
		GTT Val				600

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410 PATENT NO. 6,355,245



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. (Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO : 6,355,245 B1

DATED : Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 123, lines 34-48, and insert therefor:

		GTA Val 205			•	630
	 	 GAG Glu 215				660
		TAT Tyr 225				690
		TTT Phe 235				720
	 	 ACT Thr 245		TGA		747

Please delete column 125, lines 2-13, and insert therefor:

ATG	GCC	GAT	ATC	CAG	ATG	ACC	CAG	TCC	CCG		30
Met	Ala	Asp	Ile	Gln	Met	Thr	Gln	Ser	Pro	•	
1				5					10		
		CTG									60
Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly	Asp	Arg		
				15					20		
GTC	ACC	ATC	ACC	TGC	CGT	GCT	AGC	GAA	AAC		90
Val	Thr	Ile	Thr	Cys	Arg	Ala	Ser	Glu	Asn		
				25					30		
ATC	TAT	GGC	GCG	CTG	AAC	TGG	TAT	CAA	CAG		120
Ile	Tyr	Gly	Ala	Leu	Asn	Trp	Tyr	Gln	Gln		
	•	•		35					40		

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410 PATENT NO. <u>6,355,245</u>



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. (Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO : 6,355,245 B1

DATED : Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 125, lines 14-43, and insert therefor:

	AAA	ССТ	GGG	AAA	GCT	CCG	AAG	CTT	CTG	ATT		150
				Lys								
	-, -		•	•	45		_			50		
	TAC	GGT	GCG	ACG	AAC	CTG	GCA	GAT	GGA	GTC	'.	180
	Tyr	Gly	Ala	Thr	Asn	Leu	Ala	Asp	Gly			
					55					60		
						~~.	maa	000	maa	<i>c</i> c.»		210
				TTC								210
	Pro	ser	Arg	Phe	65	GIY	ser	Gry	Ser	70		
					65					70		
	ACG	GAT	TTC	ACT	CTG	ACC	ATC	AGC	AGT	CTG		240
				Thr								
	• • • •				75					80		
	CAG	CCT	GAA	GAC	TTC	GCT	ACG	TAT	TAC	TGT		270
	Gln	Pro	Glu	Asp	Phe	Ala	Thr	Tyr	Tyr	Cys		
					85					90		
												300
				TTA								300
	Gln	Asn	Val	Leu		Thr	Pro	Leu	Inr	100		
					95					100		
	CCA	CAG	CCT	ACC	AAG	GTG	GAA	АТА	AAA	CGT		330
				Thr								
	0+1	Ų	017		105				-,-	110		
	ACT	GGC	GGT	GGT	GGT	TCT	GGT	GGC	GGT	GGA		360
	Thr	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly		
					115				•	120		
									~			390
•										CTG		390
	Ser	GIY	Gly	GIY			GIN	vai	GIN	Leu 130		
					125					130		
	стс	CAA	тсс	GGC	י פרר	GAG	GTC	' AAG	AAG	CCA		420
										Pro		
				1	135				- 2 -	140		

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410 PATENT NO. 6,355,245



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. (Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO

: 6,355,245 B1

DATED

: Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 125, line 44, through column 127, line 15, and insert therefor:

 		GTG Val				450
 		TCT Ser				480
		GCC Ala				510
		GAG Glu				540
		TAT Tyr				570
		ATG Met				600
		TAC Tyr				630
		GAC Asp				660
 	 	 TTT Phe				690
		GAT Asp				720

PATENT NO. _6,355,245_

No. of additional copies

MAILING ADDRESS OF SENDER: Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410

PATENT NO

: 6,355,245 B1

DATED

: Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 127, lines 16-18, and insert therefor:

GGA ACC CTG GTC ACT GTC TCG AGC TGA 747 Gly Thr Leu Val Thr Val Ser Ser

Please delete column 127, lines 29-52, and insert therefor:

GCC Ala				 	30
TCC Ser					60
ACC Thr				_	90
TAT Tyr					120
CCT Pro					150
GGT Gly					180
TCT Ser					210
GAT Asp					240

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410

PATENT NO. 6,355,245



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. (Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO : 6,355,245 B1

DATED : Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 127, line 53, through column 129, line 24, and insert therefor:

		GAC Asp					270
		 TTA Leu					300
		 ACC Thr	_				330
		 GGT Gly		 			360
		 GGC Gly					390
		 GGC Gly					420
		GTC Val					450
		ATT Ile					480
		 CGT Arg					510
	-	ATG Met					540

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410 PATENT NO. 6,355,245

No. of additional copies



Burden Hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comment on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. (Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO : 6,355,245 B1

DATED : Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 129, lines 25-45, and insert therefor:

	 	ACC Thr	-				570
		GTT Val					600
	 	ACA Thr				·	630
		TCG Ser					660
	 	CGT Arg					690
		TAT Tyr					720
		GTC Val			TGA		747

Please delete column 129, line 56, through column 131, line 3, and insert therefor:

ATG	GCC	GAT	ATC	CAG	ATG	ACC	CAG	TCC	CCG		30
Met	Ala	Asp	Ile	Gln	Met	Thr	Gln	Ser	Pro		
1				5					10		
TCC	TCC	CTG	TCC	GCC	TCT	GTG	GGC	GAT	AGG		60
Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly	Asp	Arg		
				15					20	•	

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410 PATENT NO. : 6,355,245



PATENT NO : 6,355,245 B1

DATED : Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 131, lines 4-33, and insert therefor:

	ACC Thr				9	90
	GCG Ala				12	20
 	 AAA Lys	 			15	50
	ACG Thr				18	80
	TTC Phe				21	10
	ACT Thr				24	40
	GAC Asp				27	70
	TTA Leu				3(00
	ACC Thr				3:	30
 	 GGT Gly					60

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410 PATENT NO. 6,355,245



PATENT NO : 6,355,245 B1

DATED : Mar. 12, 2002

INVENTOR(S) : Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 131, line 34, through column 133, line 3, and insert therefor:

TCT Ser	GGT	GGT Gly	GGC Gly	GGT Gly 125	Ser	CAA Gln	GTC Val	CAA Gln	CTG Leu 130		390
GTG Val	CAA Gln	TCC Ser	GGC Gly	GCC Ala 135	GAG Glu	GTC Val	Lys	AAG Lys	CCA Pro 140		420
GGG Gly	GCC Ala	TCA Ser	GTC Val	Lys 145	GTG Val	TCC	TGT Cys	AAA Lys	GCT Ala 150	· .	450
AGC Ser	GGC Gly	TAT Tyr	ATT	TTT Phe 155	TCT Ser	AAT Asn	TAT Tyr	TGG Trp	ATT Ile 160	•	480
CAA Gln	TGG Trp	GTG Val	CGT Arg	CAG Gln 165	GCC Ala	CCC Pro	GGG Gly	CAG Gln	GGC Gly 170	9	510
CTG Leu	GAA Glu	TGG Trp	ATG Met	GGT Gly 175	GAG Glu	ATC Ile	TTA Leu	CCG Pro	GGC Gly 180	2	540
TCT Ser	GGT Gly	AGC Ser	ACC Thr	GAA Glu 185	TAT Tyr	GCC Ala	CAA Gln	AAA Lys	TTC Phe 190	S	70
CAG Gln	GGC Gly	CGT Arg	GTT Val	ACT Thr 195	ATG Met	ACG Thr	CGT Arg	GAC Asp	ACT Thr 200	6	00
TCG Ser	ACT Thr	AGT Ser	ACA Thr	GTA Val 205	TAC Tyr	ATG Met	GAG Glu	CTC Leu	TCC Ser 210	6	30
AGC Ser	CTG Leu	CGA Arg	TCG Ser	GAG Glu 215	GAC Asp	ACG Thr	GCC Ala	GTC Val	TAT Tyr 220	6	60

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410 PATENT NO. 6,355,245



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. (Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO

: 6,355,245 B1

DATED

: Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 133, lines 4-12, and insert therefor:

		GCG Ala								690
ıyr	cys	AIA	Arg	225	riie	rile	GIY	261	230	
CCG	ΔΔΤ	TGG	 ТДТ	· TTT	CAT	стт	TGG	GGT	CAA	720
		Trp				-				
				235					240	
GGA	ACC	CTG	GTC	ACT	GTC	TCG	AGC	TGA		747
Gly	Thr	Leu	Val		Val	Ser	Ser			
				245						

Please delete column 133, lines 22-45, and insert therefor:

 		 		•
	ATC CAG Ile Gln 5		Ser Pr	
 	TCC GCC Ser Ala 15		Asp Ar	
	ACC TGC Thr Cys 25		Glu As	
 	GCG CTG Ala Leu 35		Gln Gl	
 	AAA GCT Lys Ala 45		Leu I	
 	ACG AAC Thr Asn 55		Gly Va	

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410

PATENT NO. 6,355,245

No. of additional copies



Burden Hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comment on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PATENT NO : 6,355,245 B1

DATED : Mar. 12, 2002

INVENTOR(S) : Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 133, line 46, through column 135, line 12, and insert therefor:

	TCT Ser									210
	GAT Asp									240
	CCT Pro									270
	AAC Asn									300
	CAG Gln									330
ACT Thr	GGC Gly	GGT Gly	GGT Gly	GGT Gly 115	TCT Ser	GGT Gly	GGC Gly	GGT Gly	GGA Gly 120	360
	GGT Gly									390
	CAA Gln									420
GGG Gly	GCC Ala	TCA Ser	GTC Val	AAA Lys 145	GTG Val	TCC Ser	TGT Cys	AAA Lys	GCT Ala 150	450
AGC Ser	GGC Gly		Ile							480

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410 PATENT NO. <u>6,355,245</u>

No. of additional copies

□> 0

PATENT NO : 6,355,245 B1

DATED : Mar. 12, 2002

INVENTOR(S) : Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 135, lines 13-39, and insert therefor:

CAA Gln	TGG	GTG Val	CGT	CAG Gln 165	GCC Ala	Pro	GGG Gly	CAG Gln	GGC Gly 170	510
CTG Leu	GAA Glu	TGG Trp	ATG Met	GGT Gly 175	GAG Glu	ATC Ile	TTA Leu	CCG Pro	GGC Gly 180	540
			ACC Thr							570
AAA Lys	GAC Asp	CGT Arg	GTT Val	ACT Thr 195	ATG Met	ACG Thr	CGT Arg	GAC Asp	ACT Thr 200	600
			ACA Thr							630
			TCG Ser							660
			CGT Arg							690
CCG Pro	AAT Asn	TGG Trp	TAT Tyr	TTT Phe 235	GAT Asp	GTT Val	TGG Trp	GGT Gly	CAA Gln 240	720
			GTC Val					TGA		747

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410 PATENT NO. <u>6,355,245</u>



PATENT NO : 6,355,245 B1

DATED : Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 135, line 49, through column 137, line 21, and insert therefor:

					ATG Met					. 30	0
					TCT Ser					60	0
					GGC Gly					90	0
ATC Ile	TAT Tyr	GGC Gly	GCG Ala	CTG Leu 35	AAC Asn	TGG Trp	TAT Tyr	CAA Gln	CAG Gln 40	120	э
					CCG Pro					150	3
					CTG Leu					180)
CCT Pro	TCT Ser	CGC Arg	TTC Phe	TCT Ser 65	GGA Gly	TCC Ser	GGC Gly	TCC Ser	GGA Gly 70	210)
					ACC Thr					240)
					GCT Ala					270)
					ACT Thr					300)

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410 PATENT NO. <u>6,355,245</u>

PATENT NO : 6,355,245 B1

DATED : Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 137, lines 22-51, and insert therefor:

GGA Gly	CAG Gln	GGT Gly	ACC Thr	AAG Lys 105	GTG Val	GAA Glu	ATA Ile	AAA Lys	CGT Arg 110		330
			GGT Gly								360
TCT Ser	GGT Gly	GGT Gly	GGC Gly	GGT Gly 125	TCT Ser	CAA Gln	GTC Val	CAA Gln	CTG Leu 130		390
			GGC Gly								420
GGG Gly	GCC Ala	TCA Ser	GTC Val	AAA Lys 145	GTG Val	TCC Ser	TGT Cys	AAA Lys	GCT Ala 150		450
AGC Ser	GGC Gly	TAT Tyr	ATT Ile	TTT Phe 155	TCT Ser	AAT Asn	TAT Tyr	TGG Trp	ATT Ile 160		480
			CGT Arg							,	510
			ATG Met							!	540
			ACC Thr							!	570
AAA Lys	GAC Asp	CGT Arg	GTT Val	ACT Thr 195	ATG Met	ACG Thr	CGT Arg	GAC Asp	ACT Thr 200	e	500

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410

PATENT NO. 6,355,245

PATENT NO

: 6,355,245 B1

DATED

: Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 137, line 52, through column 139, line 6, and insert therefor:

ACT Thr						630
CTG Leu						660
TGC Cys					•	690
AAT Asn					•	720
ACC Thr				TGA	7	747

Please delete column 139, lines 16-27, and insert therefor:

30							ATC Ile			
	10					5				1
60	AGG	GAT	GGC	GTG	TCT	GCC	TCC	CTG	TCC	TCC
		Asp	Gly	Val	Ser		Ser	Leu	Ser	Ser
	20					15				
90	AAC	GAA	AGC	GCT	CGT	TGC	ACC	ATC	ACC	GTC
-	Asn	Glu	Ser	Ala	Arg		Thr	Ile	Thr	Val
	30					25				
120	CAG	CAA	TAT	TGG	AAC	CTG	GCG	GGC	TAT	ATC
120						Leu	Ala			
	40					35				

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410

PATENT NO. 6,355,245

No. of additional copies

Burden Hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comment on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PATENT NO

: 6,355,245 B1

DATED

: Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 139, lines 28-57, and insert therefor:

AAA Lys	Pro	GGG Gly	AAA Lys	GCT Ala 45		AAG Lys	CTT	CTG	ATT Ile 50		150
TAC Tyr	GGT Gly	GCG Ala	ACG Thr	AGC Ser 55	CTG Leu	CAG Gln	TCT Ser	GGA Gly	GTC Val 60		180
CCT Pro	TCT Ser	CGC Arg	TTC Phe	TCT Ser 65	GGA Gly	TCC Ser	GGC Gly	TCC Ser	GGA Gly 70	:	210
ACG Thr	GAT Asp	TTC Phe	ACT Thr	CTG Leu 75	ACC Thr	ATC Ile	AGC Ser	AGT Ser	CTG Leu 80	:	240
CAG Gln	CCT Pro	GAA Glu	GAC Asp	TTC Phe 85	GCT Ala	ACG Thr	TAT Tyr	TAC Tyr	TGT Cys 90	;	270
CAG Gln	AAC Asn	GTT Val	TTA Leu	AAT Asn 95	ACT Thr	CCG Pro	TTG Leu	ACT Thr	TTC Phe 100	3	300
GGA Gly	CAG Gln	GGT Gly	ACC Thr	AAG Lys 105	GTG Val	GAA Glu	ATA Ile	AAA Lys	CGT Arg 110	3	330
ACT Thr	GGC Gly	GGT Gly	GGT Gly	GGT Gly 115	TCT Ser	GGT Gly	GGC Gly	GGT Gly	GGA Gly 120	3	360
TCT Ser	GGT Gly	GGT Gly	GGC Gly	GGT Gly 125	TCT Ser	CAA Gln	GTC Val	CAA Gln	CTG Leu 130	3	90
GTG Val	CAA Gln	TCC Ser	GGC Gly	GCC Ala 135	GAG Glu	GTC Val	AAG Lys	AAG Lys	CCA Pro 140	4	20

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410

PATENT NO. 6,355,245

PATENT NO : 6,355,245 B1

DATED : Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 141, lines 1-30, and insert therefor:

						- •	,		,	una	11 130	· · · · ·		•
GGC Gly	GCC Ala	TCA Ser	GTC Val	Lys	Val	Ser	TGT Cys	'AAA Lys	GCT Ala 150					450
AGC Ser	GGC	TAT Tyr	ATT	TTT Phe	Ser	AAT Asn	TAT	TGG Trp	ATT Ile 160					480
CAA Gln	TGG Trp	GTG Val	CGT Arg	CAG Gln 165	GCC Ala	CCC Pro	GGG Gly	CAG Gln	GGC					510
CTG Leu	GAA Glu	TGG Trp	ATG Met	GGT	GAG Glu	ATC Ile	TTA Leu	CCG Pro	GGC Gly					540
TCT Ser	GGT Gly	AGC Ser	ACC Thr	GAA	TAT Tyr	ACC Thr	GAA Glu	AAT Asn	Phe				!	570
AAA Lys	GAC Asp	CGT Arg	GTT Val	ACT Thr	ATG Met	ACG Thr	CGT Arg	GAC Asp	Thr					600
TCG Ser	ACT Thr	AGT Ser	ACA Thr	Val	TAC Tyr	ATG Met	GAG Glu	CTC Leu	TCC Ser				•	630
AGC Ser	CTG Leu	CGA Arg	TCG Ser	GAG Glu	GAC Asp	ACG Thr	GCC Ala	GTC Val	210 TAT				6	560
тат	TGC	GCG	CGT	215 TAT	TTT Phe	TTT	GGT	тст	220 AGC				e	590
CCG	AAT	TGG	TAT	225 TTT	GAT	GTT	TGG	GGT	230 CAA				7	720
210	កខារ	тър	ıyr	235	Asp	vaı	rrp	Gly	Gln 240					

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410

PATENT NO. 6,355,245

No. of additional copies

0

Burden Hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comment on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PATENT NO

: 6,355,245 B1

DATED

: Mar. 12, 2002

INVENTOR(S): Mark J. EVANS et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Please delete column 141, lines 31-33, and insert therefor:

GGA ACC CTG GTC ACT GTC TCG AGC TGA Gly Thr Leu Val Thr Val Ser Ser 245

MAILING ADDRESS OF SENDER:

Stephen A. Saxe Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire, CT 06410

PATENT NO. 6,355,245

No. of additional copies



Burden Hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comment on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

FOR SEQ ID NO:15, THE NEGATIVE NUMBERING IS INCORRECTLY SHOWN IN SEQUENCE LISTING AS SUBMITTED. SHOULD THIS BE CORRECTED?